

AN EASY REGIO- AND STEREOSELECTIVE SYNTHESIS OF A VERSATILE TRISACCHARIDE PRECURSOR FOR SYNTHETIC CARBOHYDRATE BASED VACCINES

Juan A. MESA^{a1,*}, Juan E. TACORONTE^{a2}, Ernesto GARCÍA^b and Jorge LEYVA^c

^a Centro de Ingeniería e Investigaciones Químicas, Vía Blanca s/n entre Infanta y Palatino, Cerro, Ciudad de La Habana, Cuba; e-mail: ¹ johnant2001@yahoo.es, ² jetacoronte@yahoo.com

^b Centro de Estudio de Antígenos Sintéticos, Facultad de Química, Universidad de La Habana, Cuba; e-mail: mercyvaldes@infomed.sld.cu

^c Empresa Farmacéutica "Mario Muñoz", Hacendado 1, Habana Vieja, Ciudad de La Habana, Cuba; e-mail: tony2@ciiq.minbas.cu

Received October 13, 2006


Accepted March 4, 2007

The trisaccharide allyl 2-deoxy-2-phthalimido-6-*O*-[4-*O*-(2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranosyl]- β -D-glucopyranoside (**3**) was prepared directly from acceptor allyl 2-deoxy-2-phthalimido- β -D-glucopyranoside (**1**) and 4-*O*-(2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- α -D-glucopyranosyl trichloroacetimidate (**2c**) using regio- and stereoselective synthesis in dichloromethane with trimethylsilyl triflate as a promoter.

Keywords: Trisaccharides; Oligosaccharides; Carbohydrates; Glycosidation; Regioselective synthesis; Stereoselective synthesis.

In many countries, the pneumonia caused by *Streptococcus pneumoniae* is the biggest bacteriological cause of death in children younger than 5 years and in adults over 50. Approximately 5 million children die every year of pneumonia^{1,2}, 27% of that induced by *S. pneumoniae* (>85 serotypes). The capsular polysaccharide is the essential factor of virulence in the *S. pneumoniae* serotype 14. Some efforts are focused on the synthesis of its structure unit, a tetrasaccharide fragment $\{\rightarrow 3\}\text{-}\beta\text{-D-Galp-(1}\rightarrow 4\text{)}\text{-}\beta\text{-D-Glcp-(1}\rightarrow 6\text{)}\text{-}[\beta\text{-D-Galp-(1}\rightarrow 4\text{)}]\text{-}\beta\text{-D-GlcpNAc-(1}\rightarrow \text{)}_n$, for preparation of an antigen, useful in obtaining synthetic vaccines³⁻⁵. Bearing in mind the significance of developing new methodological approaches for preparation of this unit, we report here the synthesis of the precursor trisaccharide allyl 2-deoxy-2-phthalimido-6-*O*-[4-*O*-(2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranosyl]- β -D-glucopyranoside (**3**), directly from allyl 2-deoxy-2-phthalimido- β -D-glucopyranoside (**1**) (acceptor triol)

and trichloroacetimidate **2c** (Scheme 1) using regio- and stereoselective procedures, through reactions of OH at C-6 and C-1 in dichloromethane, using trimethylsilyl trifluoromethanesulfonate (TfOTMS) as a promoter.




(i) ethanolamine, ethyl acetate; (ii) CCl_3CN , K_2CO_3 , CH_2Cl_2

SCHEME 1

RESULTS AND DISCUSSION

The literature survey reveals that synthetic procedures for obtaining trisaccharide fragments are too long and include very tedious and time-consuming work-up operations. We avoid the use of boron trifluoride etherate as a promoter in the glycosylation^{6,7}, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and polymer complexes PS-DBU as bases for generating an imidate precursor, employing TfOTMS as a sole promoter for glycosylation and K_2CO_3 (ref.⁸) as a promoter base for obtaining the imidate, which allows to reach very satisfactory yields of **3** under more accessible conditions (Scheme 2, >70%). Our strategy was focused on the previously described⁵ lactosylation of the primary OH group in position C-6 in acceptor triol **1**, taking into account its highest reactivity in comparison with OH groups in positions C-3 and C-4 of **1**. The lactosylation of triol **1** with **2c** minimizes the number of reaction steps and optimizes the synthesis of **3** because it is not necessary to protect OH functionalities in positions C-3 and C-4 in the starting triol **1** (ref.⁵). The synthetic scheme is very simple: perbenzoylated lactose **2a** was selectively debenzoylated in the anomeric position C-1 using an ethanolamine-ethyl acetate mixture and **2b** (>90%) was obtained. It is noteworthy to comment in this context that the use of anhydrous hydrazine acetate in anhydrous DMF⁹, a very complex and expensive system for deprotecting anomeric position (C-1 in **2b**) does not work so well. The position C-1 in **2b** was *O*-alkylated with trichloroacetonitrile- K_2CO_3 in dichloromethane to obtain **2c**. The observed signal (singlet) at 8.65 ppm corroborates the presence of the imidate group at position C-1 in **2c** with α -configuration (anomeric proton signal 6.71 ppm, $J(1,2) = 3.7$ Hz). It is to be noted that this is the first report on the direct coupling of triol acceptor

1 with a disaccharide (lactose) imidate **2c** giving a trisaccharide with a satisfactory yield (>70%) of desired stereochemistry (100% β). To confirm the stereochemistry of the desired **3**, the coupling constants for anomeric protons were determined. The values of coupling constants for anomeric protons: H-1, $J(1,2) = 8.5$ Hz (d, 5.14 ppm); H-1', $J(1',2') = 7.8$ Hz (d, 4.93 ppm) and H-1'', $J(1'',2'') = 9.5$ Hz (d, 5.07 ppm) confirm the β -configuration of all anomeric carbons in **3**.



SCHEME 2

On the other hand, the use of protecting (participating) groups in the position C-2 (OBz) allows to obtain the β -derivative through blocking the α -face of the generated carbocation. For evaluation of the regioselectivity of the process, the variation of chemical shift ($\Delta\delta$, ppm; DEPT 135) of C-6 in the acceptor triol **1** was used. A significant deshielding of the C-6 in glucose phthalimide **1**, from 61.05 to 69.39 ppm, and deshielding of H-6 (m, Ha, Hb) from 3.90–3.97 ppm in **1** to 4.25–4.27 ppm in derivative **3** was observed^{5,10–12}. These remarkable variations confirm the glycosylation route through C-6. The use of this trisaccharide as a versatile and optimal intermediate for obtaining the tetrasaccharide unit of the vaccine will be reported elsewhere soon.

In conclusion, this method provides a novel, simpler, and convenient route for the synthesis of trisaccharide allyl 2-deoxy-2-phthalimido-6-O-[4-O-(2,3,4,6-tetra-O-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-O-benzoyl- β -D-glucopyranosyl]- β -D-glucopyranoside (**3**), a versatile precursor for synthetic

carbohydrate-based vaccines, through a regio- and stereoselective glycosylation (lactosylation) without any protection of OH at C-3, C-4 in the starting acceptor triol.

EXPERIMENTAL

Optical rotations were measured with a POLAMAT A automatic polarimeter (GDR) in 1% chloroform solutions at 25 °C. ^1H and ^{13}C NMR spectra were recorded on a Bruker AC-300 instrument at 360 MHz, chemical shifts were expressed in δ , ppm, relative to the signal for internal TMS at 25 °C, using CDCl_3 as a solvent. Coupling constants, J , are given in Hz. Column chromatography was performed on Kieselgel 60 (Merck >230 mesh, 0.040–0.63 mm) and fractions were monitored by TLC on Kieselgel 60 F254 (Merck). Detection was effected by charring with 5% H_2SO_4 -ethanol.

In work-up procedures, washings were carried three times with appropriate quantities of water, aqueous 10% NaHCO_3 or 10% NaCl solutions, unless indicated otherwise, and drying of organic solutions was performed with anhydrous calcium sulfate. Evaporations were done under reduced pressure at 40 °C. All solvents were distilled and dried before use.

4-*O*-(2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- α -D-glucopyranose (**2b**)

To a mixture of **2a** (1.04 g, 2.40 mmol) in dried ethyl acetate (25 ml), ethanolamine (0.6 ml) was added. The reaction mixture was stirred overnight (protected from light). The reaction was monitored by TLC (silica gel plates, 5:1 v/v toluene-acetone). The product was washed twice with a NaCl solution and H_2O . The organic extract was dried (anhydrous Na_2SO_4), filtered, and concentrated. The separation by column chromatography (5:1 v/v hexane-ethyl acetate) of the residue gave 0.735 g (92%) of syrupy **2b**. ^1H NMR (CDCl_3): 5.47 d, 0.95 H, $J(1,2) = 3.6$ (H-1 α); 5.40 d, 0.05 H, $J(1,2) = 9.98$ (H-1 β); 5.80 t, 1 H, $J(2,3) = 10.3$ (H-3); 5.75 d, 1 H, $J(3',4') = 3.5$ (H-4'); 5.62 dd, 1 H, $J(2',3') = 10.5$ (H-2'); 5.50 dd, 1 H (H-2); 5.41 dd, 1 H, $J(3'-4') = 3.5$ (H-3'); 5.08 d, 1 H, $J(1',2') = 9.5$ (H-1' β); 4.72 m, 1 H (H-5'); 4.53 m, 1 H (H-5); 4.46 m, 2 H (H-6'); 4.38 m, 2 H (H-6); 4.17 dd, 1 H (H-4). ^{13}C NMR (CDCl_3): 166.2–170.8 (CO); 121.4–139.8 (Ph); 100.1 (C-1'); 91.47 (C-1); 77.2 (C-4); 76.3 (C-4'); 76.1 (C-2'); 75.3 (C-2); 72.9 (C-5); 72.5 (C-5'); 72.0 (C-3'); 71.2 (C-3); 63.4 (C-6'); 63.9 (C-6).

4-*O*-(2,3,4,6-Tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- α -D-glucopyranosyl Trichloroacetimidate (**2c**)

To **2b** (1.04 g, 2.33 mmol), previously dried overnight under vacuum, dry dichloromethane (in high-vacuum line) and activated K_2CO_3 (1.09 g) were added. To this mixture Cl_3CCN (8.1 ml, 8.16 mmol) was added under stirring in N_2 atmosphere. The reaction mixture was stirred overnight and monitored by TLC (silica gel plates, 5:1 v/v toluene-acetone). After completing the reaction, ether was added, the mixture was filtered through Celite, concentrated and the residue was purified by column chromatography (silica gel, 4:1 v/v toluene-acetone) to give 0.781 g (75%) of syrupy **2c**. ^1H NMR (CDCl_3): 8.65 s, 1 H (NH); 6.71 d, 1 H, $J(1,2) = 3.7$ (H-1 α); 5.82 t, 1 H, $J(2,3) = 10.1$ (H-3); 5.78 d, 1 H, $J(3',4') = 3.5$ (H-4'); 5.60 dd, 1 H, $J(2',3') = 10.5$ (H-2'); 5.54 dd, 1 H (H-2); 5.40 dd, 1 H, $J(3',4') = 3.5$ (H-3'); 5.03 d, 1 H,

$J(1',2') = 9.5$ (H-1' β); 4.70 m, 1 H (H-5'); 4.56 m, 1 H (H-5); 4.40 m, 2 H (H-6'); 4.30 m, 2 H (H-6); 4.07 dd, 1 H (H-4). ^{13}C NMR (CDCl_3): 161.5 (OCNHCCl₃); 166.2–170.8 (CO); 121.4–139.8 (Ph); 100.4 (C-1'); 92.5 (C-1); 79.8 (CCl₃); 76.8 (C-4); 76.2 (C-4'); 76.0 (C-2'); 75.3 (C-2); 72.9 (C-5); 72.5 (C-5'); 72.0 (C-3'); 71.2 (C-3); 63.2 (C-6'); 62.9 (C-6).

Allyl 2-Deoxy-2-phthalimido-6-*O*-[4-*O*-(2,3,4,6-tetra-*O*-benzoyl- β -D-galactopyranosyl)-2,3,6-tri-*O*-benzoyl- β -D-glucopyranosyl]- β -D-glucopyranoside (**3**)

A mixture of **2c** (2.161 g, 3.74 mmol), **1** (0.625 g, 1.79 mmol) and powdered molecular sieves (4Å, 2.5 g) was dried in high-vacuum line for 2 h. Dichloromethane (6 ml) was freshly distilled in the vacuum line onto reaction mixture, then TfOTMS (3 μl , 9.35 mmol) was added dropwise under stirring in N₂ atmosphere. Stirring at -40 °C was continued for 6 h. The reaction was monitored by TLC (silica gel plates, 4:3 v/v ethyl acetate-hexane, R_F 0.35). The reaction mixture was diluted with dichloromethane, filtered through Celite and washed with aqueous 10% NaHCO₃ solution and water, dried and concentrated. Column chromatography (silica gel, 4:3 v/v ethyl acetate-hexane) of the residue gave 0.849 g (72%) of syrupy **3**. $[\alpha]_{\text{D}}^{+16}$. For C₇₈H₆₆O₁₇N (1289.4) calculated: 72.65% C, 5.15% H, 1.08% N; found: 72.33% C, 5.09% H, 1.04% N. ^1H NMR (CDCl_3): 7.71–7.67 m, 4 H (Phth); 7.05–6.97 m, 35 H (COPh); 5.80 t, 1 H, $J(2',3') = 9.2$ (H-3'); 5.77 d, 1 H, $J(3'',4'') = 3.5$ (H-4''); 5.70 m, 1 H (OCH₂CH=CH₂); 5.61 dd, 1 H, $J(2'',3'') = 10.2$ (H-2''); 5.55 dd, 1 H, $J(2',3') = 9.3$ (H-2'); 5.42 dd, 1 H, $J(3'',4'') = 3.7$ (H-3''); 5.38 dd, 1 H (H-2); 5.14 d, _ H, $J(1,2) = 8.5$ (H-1 β); 5.10 m, 2 H (OCH₂CH=CH₂); 5.07 d, 1 H, $J(1'',2'') = 9.5$ (H-1'' β); 4.93 d, 1 H, $J(1',2') = 7.8$ (H-1' β); 4.68 m, 1 H (H-5''); 4.58 m, 1 H (H-5'); 4.47 t, 1 H (H-5); 4.41 m, 2 H (H-6''); 4.28 m, 2 H (H-6'); 4.25–4.27 m, 2 H (H-6a, H-6b); 4.09 dd, 1 H (H-4'); 3.98 m, 2 H (OCH₂CH=CH₂); 3.94 dd, 1 H (H-4); 3.82 dd, _ H (H-3). ^{13}C NMR (CDCl_3): 169.63–162.92 (9 C, COPhth, COPh); 135.21, 130.37, 123.84 (Phth); 134.11, 133.55, 133.21, 131.96, 130.28, 129.68, 128.70 (C-H); 123.22, 117.18 (OCH₂-CH=CH₂); 101.1 (C-1'); 100.98 (C-1''); 97.07 (C-1); 75.71 (C-3'); 75.25 (C-2); 74.57 (C-5''); 74.43 (C-3'); 73.88 (C-2); 73.56 (C-2''); 72.50 (C-5); 72.05 (C-4); 71.58 (C-5); 71.05 (C-4''); 70.70 (C-3); 69.39 (C-6, DEPT-135); 67.60 (C-4); 64.70 (OCH₂-CH=CH₂).

This research project was supported by University of Havana (Center for Studies of Synthetic Antigens, Faculty of Chemistry, Cuba). We would like to thank Prof. V. Verez Bencomo for his kind attention and suggestions and technician G. Alvarez for recording the ^1H and ^{13}C NMR spectra. The authors are indebted to Central Laboratories of the Cuban Institute of Sugar Cane Derivatives (ICIDCA) for elemental analyses.

REFERENCES

1. *New Vaccine Development, Establishing Priorities, Vol II: Diseases of Importance in Developing Countries*. Appendix D-16, D-17, pp. 338–375. National Academic Press, Washington D.C. 1986; <http://books.nap.edu/catalog/920.html>.
2. Mtango F. D., Neuvians E. D.: *Trans. R. Soc. Trop. Med. Hyg.* **1986**, *80*, 851.
3. Verez-Bencomo V., Fernández-Santana V., Hardí E., Toledo M. E., Rodríguez M. C., Heynngnezz L., Rodríguez A., Baly A., Herrera L., Izquierdo M., Villar A., Valdés Y., Cosme K., Deler M. L., Montane M., Garcia E., Ramos A., Aguilar A., Medina E.,

- Toraño G., Sosa I., Hernandez I., Martínez R., Muzachioc A., Carmenates A., Costa L., Cardoso L., Campa C., Diaz M., Roy R.: *Science* **2004**, *305*, 522.
4. Toraño G., Toledo M. E., Baly A., Fernandez V., Rodriguez F., Alvarez Y., Serrano T., Musachio A., Hernandez I., Hardí E., Rodríguez A., Hernandez H., Aguilar A., Sánchez R., Diaz M., Muzio V., Dfana J., Rodríguez M. C., Heynngnezz L., Verez-Bencomo V.: *Clin. Vaccine Immunol.* **2006**, *13*, 1052.
5. Koeman F., Meissner J., Kamerling J., Vliegenthart J., van Ritter H.: *J. Carbohydr. Chem.* **1994**, *13*, 1.
6. Schmidt R.: *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 212.
7. a) Sato S., Ito Y., Nukada T., Nakahara Y., Ogawa T.: *Carbohydr. Res.* **1987**, *167*, 197;
b) Chiara J. L., Encinas L., Diaz B.: *Tetrahedron Lett.* **2005**, *46*, 2445.
8. Schimdt R., Michel R., Ross M.: *Liebigs Ann. Chem.* **1984**, 1343.
9. Excoffier G., Gagnaire D., Utille J.-P.: *Carbohydr. Res.* **1975**, *39*, 368.
10. Marion D., Wutrich K.: *Biochem. Biophys. Res. Commun.* **1983**, *113*, 967.
11. Bax A., Davis D. G.: *J. Magn. Reson.* **1985**, *65*, 355.
12. Sinay P.: *Pure Appl. Chem.* **1978**, *50*, 1437.